Great Lakes NeuroTechnologies receives UKCA mark for KinesiaU™ motor assessment system

01 August 2022: Independence, OH – Great Lakes NeuroTechnologies (GLNT) is proud to announce that its KinesiaU™ motor assessment system has received the UKCA mark and will now be available in the United Kingdom in addition to the United States. KinesiaU [ ] enables patients with movement disorders such as Parkinson’s disease to track their tremor, slowness, and dyskinesia in response to therapy using an app on their personal smartwatch and smartphone. Patients view their symptoms in user-friendly reports on their smartphones and clinicians access their patients’ data in real-time through the KinesiaU provider portal to help make better care decisions and identify therapies and activities to improve their patients’ symptoms.

According to GLNT President and COO, Dustin Heldman, Ph.D., “We are thrilled to receive the UKCA mark and make our KinesiaU product available to patients in the UK. This will allow the 150,000 people in the UK living with Parkinson’s disease to better monitor their symptoms and help their doctors manage their therapies.”

Based on Great Lakes NeuroTechnologies’ 15 years of development and validation of its FDA-cleared Kinesia™ technology, which is patented in the US and various countries in Europe including the UK, KinesiaU is the only validated system for real-time remote patient monitoring of Parkinson’s disease with 24/7 clinician access to their patients’ data. The KinesiaU motor assessment system is currently available in the UK in consultation with the patient’s clinician as well as in the US by prescription.

About Great Lakes NeuroTechnologies

Great Lakes NeuroTechnologies [ ] is committed to pioneering innovative biomedical technologies to serve research, education, and medical communities, improving access to medical technology for diverse populations, and positively impacting quality of life for people around the world.

About Kinesia™ Technology

GLNT commercialized Kinesia™ technology to provide wearable, objective and automated assessment of movement disorders such as Parkinson’s disease (PD) and essential tremor (ET). The clinically validated technology has been adopted as the gold-standard for objective sensor measurement for movement disorders by many of the world’s leading pharmaceutical and medical device companies. The technology is protected by US and international patents listed at

Media Relations

Bill Bauza 216-446-2431

Leave a Reply